Our Perspective
-
Opportunity Is Knocking - Will You Answer?
By Steve Rowley November 13, 2017English
Gen Re has just completed our 16th annual U.S. Critical Illness Market Survey. The data gathered from 53 participating carriers captures a moment-in-time snapshot of where the market is today. This snapshot comes to life when we look to the historical...
Read More -
How Deep Brain Stimulation Helps Manage Neurological Disorders
By Dr. Chris Ball October 24, 2017English
Using electrical stimulation to manage brain disorders has a long and chequered history. Deep Brain Stimulation (DBS) is the latest. It involves implanting electrodes, connected to a computerized pulse generator, deep into the structure of the brain....
Read More -
Advances in Medical Diagnosis and Treatment - Risk or Opportunity for Critical Illness Insurance?
By Steve Rowley October 10, 2017English
Medicine is changing - but what that means to patients and insurers could mean very different things. Even within our world of insurance, the answer will vary by product. Will rapid advancements in cancer diagnosis and treatment mean greater profits...
Read More -
New Diagnostics and a Future for Critical Illness Insurance
By Ross Campbell October 05, 2017English
Millions have benefitted from the cushion Critical Illness (CI) products provide to financial hardship linked to a cancer diagnosis, stroke or heart attack. CI has also been rewarding for providers, not just by helping them remain relevant but by also...
Read More -
Are Functional Neurological Symptoms the “Great Deceivers”?
By Dr. Chris Ball September 14, 2017English
Neurological symptoms that lack an underlying structural abnormality cause significant distress and disability for those who experience them. Investigation and management consume large amounts of clinical resources. For insurers, neurological symptoms...
Read More -
New Cancer Diagnostics - A Threat to Critical Illness Cover?
By Karin Brendel August 28, 2017English Deutsch
A consensus among medical experts is that histopathology will lose its importance in selecting appropriate cancer treatment, and eventually diagnosis, over the course of the next 15 years. During this time, liquid biopsy techniques targeted at finding...
Read More
Featured Multimedia
View all multimedia
Most Popular
Topics
Capital Management
Life/Health
Property/Casualty
Contributors
Get to know our global experts
